The performance of the s.p. for the last year should make clear to everyone that we are not going anywhere without late stage results. No one will touch this stock based on pre-clinical or early stage trials. Interim results if good, while not definitive, will be enough to get some to take a chance. There is no correlation between full enrollment and success and that is why that press release will do nothing. If big pharma. was gong to jump in before interim results, they would have done so already. There are no catalysts between now and mid-year so it is going to be a long winter.
Market Data 
Markets 
AI
